X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pr-171 (25) 25
bortezomib (21) 21
index medicus (21) 21
humans (20) 20
irreversible inhibitor (15) 15
multiple myeloma - drug therapy (14) 14
carfilzomib (12) 12
multiple myeloma (11) 11
oligopeptides - adverse effects (11) 11
oncology (10) 10
proteasome inhibitors (10) 10
antineoplastic agents - therapeutic use (9) 9
oligopeptides - therapeutic use (9) 9
antineoplastic agents - adverse effects (8) 8
female (8) 8
male (8) 8
oligopeptides - administration & dosage (8) 8
pharmacology & pharmacy (8) 8
adult (7) 7
aged (7) 7
middle aged (7) 7
multiple-myeloma (7) 7
proteasome inhibitor (7) 7
proteasome inhibitor carfilzomib (7) 7
antineoplastic agents - pharmacology (6) 6
boronic acids - therapeutic use (6) 6
dose-response relationship, drug (6) 6
hematology (6) 6
multiple myeloma - pathology (6) 6
oligopeptides - pharmacology (6) 6
open-label (6) 6
potent (6) 6
proteasome inhibitors - adverse effects (6) 6
recurrence (6) 6
single-agent carfilzomib (6) 6
article (5) 5
drug therapy (5) 5
pharmacokinetics (5) 5
proteasome inhibitors - therapeutic use (5) 5
pyrazines - therapeutic use (5) 5
therapy (5) 5
aged, 80 and over (4) 4
antineoplastic agents - administration & dosage (4) 4
clinical trials as topic (4) 4
dosage and administration (4) 4
drug resistance, neoplasm (4) 4
myeloma (4) 4
treatment outcome (4) 4
animals (3) 3
apoptosis (3) 3
apoptosis - drug effects (3) 3
arm (3) 3
boronic acids - pharmacology (3) 3
cell line, tumor (3) 3
disease-free survival (3) 3
models (3) 3
oligopeptides - chemistry (3) 3
oligopeptides - pharmacokinetics (3) 3
peptides (3) 3
protease inhibitors - therapeutic use (3) 3
proteasome inhibitors - administration & dosage (3) 3
proteasome inhibitors - pharmacology (3) 3
proteins (3) 3
pyrazines - pharmacology (3) 3
ubiquitin (3) 3
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - chemistry (2) 2
antitumor-activity (2) 2
biochemistry & molecular biology (2) 2
boronic acids (2) 2
boronic acids - adverse effects (2) 2
care and treatment (2) 2
cell survival - drug effects (2) 2
cells (2) 2
chemical properties (2) 2
chemotherapy (2) 2
clinical trials (2) 2
clinical trials, phase ii as topic (2) 2
combination therapy (2) 2
disease progression (2) 2
dose dexamethasone (2) 2
drug administration schedule (2) 2
drug approval (2) 2
drug evaluation, preclinical (2) 2
drugs (2) 2
enzyme inhibitors (2) 2
fatigue - chemically induced (2) 2
hematologic malignancies (2) 2
hematology, oncology and palliative medicine (2) 2
hemic and lymphatic diseases (2) 2
in-vitro (2) 2
lenalidomide (2) 2
leukemia, myeloid, acute - drug therapy (2) 2
leukemia, myeloid, acute - pathology (2) 2
lymphoma - pathology (2) 2
medicine & public health (2) 2
metabolism (2) 2
neutropenia - chemically induced (2) 2
pathway (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2013, Volume 19, Issue 8, pp. 2248 - 2256
Journal Article
Journal Article
BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, ISSN 0006-9248, 2019, Volume 120, Issue 6, pp. 468 - 475
BACKGROUND: Previous studies on the efficacy of platinum-based drugs and selective inhibitors of proteasome have revealed promising outcomes. This study is... 
PROTEASOME INHIBITOR CARFILZOMIB | BCRP | APOPTOSIS | NONSMALL CELL | CANCER CELLS | drug combination | carfilzomib | BORTEZOMIB | ANTITUMOR-ACTIVITY | ovarian neoplasms | MEDICINE, GENERAL & INTERNAL | IN-VITRO | cisplatin | PR-171 | EXPRESSION | Index Medicus
Journal Article
Organic & Biomolecular Chemistry, ISSN 1477-0520, 2014, Volume 12, Issue 30, pp. 5710 - 5718
Peptide epoxyketones are potent and selective proteasome inhibitors. Selectivity is governed by the epoxyketone dual electrophilic warhead, which reacts with... 
POTENT | ACIDS | CRYSTAL-STRUCTURE | SITES | CHEMISTRY, ORGANIC | BORTEZOMIB | PR-171 | MOTIF | PROBES | Protein Carbonylation | Peptides - chemistry | Epoxy Compounds - chemistry | Humans | HEK293 Cells | Proteasome Inhibitors - chemistry | Oligopeptides - chemistry | Electrons | Index Medicus
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2011, Volume 17, Issue 7, pp. 1753 - 1764
Journal Article
Journal of Chemical Research, ISSN 1747-5198, 02/2016, Volume 40, Issue 2, pp. 82 - 86
A novel and efficient preparation of epoxyketone intermediates for the synthesis of carfilzomib and its derivatives has been developed. Compared to reported... 
Carfilzomib | Epoxyketone derivatives | Vanadium(III) acetylacetonate | epoxyketone derivatives | PR-171 | PROTEASOME INHIBITORS | CHEMISTRY, MULTIDISCIPLINARY | carfilzomib | vanadium(III) acetylacetonate | Synthesis | Scaling up | Derivatives
Journal Article
OncoTargets and Therapy, ISSN 1178-6930, 2012, Volume 5, Issue default, pp. 237 - 244
Carfilzomib is a second-generation proteasome inhibitor with well-documented clinical activity as a single agent in patients with relapsed/refractory multiple... 
Refractory | Carfilzomib | Myeloma | Proteasome inhibitor | Relapsed | refractory | CELLS | carfilzomib | PROTEASOME INHIBITORS INDUCE | BORTEZOMIB RESISTANCE | myeloma | proteasome inhibitor | PSMB5 | PROFILE | GENE | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | MUTATION | relapsed | PROTEINS | PR-171 | IRREVERSIBLE INHIBITOR | Relapse | Multiple myeloma | Dosage and administration | Research | Drug therapy | Cancer
Journal Article
Formulary, ISSN 1082-801X, 2012, Volume 47, Issue 8, pp. 282 - 308
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 09/2009, Volume 34, Issue 9, pp. 708 - 716
Proteosome inhibitors ore a new class of drugs that hove been shown to be cytotoxic and to induce apoptosis in tumor cells, particularly multiple myelomo (MM).... 
TARGET | MODELS | PHARMACOLOGY & PHARMACY | PR-171 | PROTEASOME INHIBITORS | IRREVERSIBLE INHIBITOR
Journal Article
Journal Article